상담문의입니다.
페이지 정보
작성자 Danuta
작성일 : 2024-02-27 04:45
작성일 : 2024-02-27 04:45
본문
메세지 내용
Ue for tendon tissue engineering. J Tissue Eng Regen Med 2013. doi:10.1002/term.1791. Tan Q, Lui bmjopen-2016-011824 PP, Rui YF: Effect of in vitro passaging on the stem cell-related properties of tendon-derived stem cells-implications in tissue engineering. Stem Cells Dev 2012, 21:790?00.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submitdoi:10.1186/scrt475 Cite this article as: Mienaltowski et al.: Tendon proper- and peritenon-derived progenitor cells have unique tenogenic properties. Stem Cell Research Therapy 2014 5:86.
Liu et al. Stem Cell Research Therapy 2014, 5:111 http://stemcellres.com/content/5/5/RESEARCHOpen AccessPreconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis 4-(Thiophen-2-yl)pyridin-3-amine in vitro and after transplantation into the ischemic heart of ratsXian-Bao Liu1,2, Jian-An Wang1, Xiao-Ya Ji2, Shan Ping Yu2 and Ling Wei2*AbstractIntroduction: Poor cell Methyl 2-((4-nitro-1h-pyrazol-1-yl)methyl)benzoate survival and limited functional benefits have restricted the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of myocardial infarction. We showed recently that hypoxia preconditioning of BMSCs and neural progenitor cells before transplantation can enhance the survival and therapeutic properties of these cells in the ischemic brain and heart. The present investigation explores a novel strategy of preconditioning BMSCs using the Hypoxia-inducible factor 1 (HIF-) prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG) to enhance their survival and therapeutic efficacy after transplantation into infarcted myocardium. Methods: BMSCs from green fluorescent protein transgenic rats were cultured with or without 1 mM DMOG for 24 hours in complete culture medium before transplantation. Survival and angiogenic factors were evaluated in vitro PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/1435082 by trypan blue staining, Western blotting, and tube formation test. In an ischemic heart model of rats, BMSCs with and without DMOG preconditioning were intramyocardially transplanted into the peri-infarct region 30 minutes after permanent myocardial ischemia. Cell death was measured 24 hours after engraftment. Heart function, angiogenesis and infarct size were measured 4 weeks later. Results: In DMOG preconditioned BMSCs (DMOG-BMSCs), the expression of survival and angiogenic factors PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16996043 including HIF-1, vascular endothelial growth factor, glucose transporter 1 and phospho-Akt were significantly increased. In comparison with control cells, DMOG-BMSCs showed higher viability and enhanced angiogenesis in both in vitro and in vivo assays. Transplantation of DMOG-BMSCs reduced heart infarct size and promoted functional benefits of the cell therapy. Conclusions: We suggest that DMOG preconditioning enhances the survival capability of BMSCs and paracrine effects with increased differentiation potential. Prolyl hydroxylase inhibition is an effective and feasible strategy to enhance therapeutic efficacy and efficiency of BMSC transplantation therapy after heart ischemia.* Correspondence: lwei7@emory.edu 2 Department of Anesthesiology, Emory University School of Medicine, 101 Woodruff Circle, Woodruff Memorial Research Building Suite 617, Atlanta, GA 30322, USA Full list of author informa.
Liu et al. Stem Cell Research Therapy 2014, 5:111 http://stemcellres.com/content/5/5/RESEARCHOpen AccessPreconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis 4-(Thiophen-2-yl)pyridin-3-amine in vitro and after transplantation into the ischemic heart of ratsXian-Bao Liu1,2, Jian-An Wang1, Xiao-Ya Ji2, Shan Ping Yu2 and Ling Wei2*AbstractIntroduction: Poor cell Methyl 2-((4-nitro-1h-pyrazol-1-yl)methyl)benzoate survival and limited functional benefits have restricted the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of myocardial infarction. We showed recently that hypoxia preconditioning of BMSCs and neural progenitor cells before transplantation can enhance the survival and therapeutic properties of these cells in the ischemic brain and heart. The present investigation explores a novel strategy of preconditioning BMSCs using the Hypoxia-inducible factor 1 (HIF-) prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG) to enhance their survival and therapeutic efficacy after transplantation into infarcted myocardium. Methods: BMSCs from green fluorescent protein transgenic rats were cultured with or without 1 mM DMOG for 24 hours in complete culture medium before transplantation. Survival and angiogenic factors were evaluated in vitro PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/1435082 by trypan blue staining, Western blotting, and tube formation test. In an ischemic heart model of rats, BMSCs with and without DMOG preconditioning were intramyocardially transplanted into the peri-infarct region 30 minutes after permanent myocardial ischemia. Cell death was measured 24 hours after engraftment. Heart function, angiogenesis and infarct size were measured 4 weeks later. Results: In DMOG preconditioned BMSCs (DMOG-BMSCs), the expression of survival and angiogenic factors PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16996043 including HIF-1, vascular endothelial growth factor, glucose transporter 1 and phospho-Akt were significantly increased. In comparison with control cells, DMOG-BMSCs showed higher viability and enhanced angiogenesis in both in vitro and in vivo assays. Transplantation of DMOG-BMSCs reduced heart infarct size and promoted functional benefits of the cell therapy. Conclusions: We suggest that DMOG preconditioning enhances the survival capability of BMSCs and paracrine effects with increased differentiation potential. Prolyl hydroxylase inhibition is an effective and feasible strategy to enhance therapeutic efficacy and efficiency of BMSC transplantation therapy after heart ischemia.* Correspondence: lwei7@emory.edu 2 Department of Anesthesiology, Emory University School of Medicine, 101 Woodruff Circle, Woodruff Memorial Research Building Suite 617, Atlanta, GA 30322, USA Full list of author informa.